Biological evaluation of 2,3-dioxoindolin-N-phenylacetamide derivatives as potent CDC25B and PTP1B phosphatase inhibitors. Braz. J. Pharm. Sci. [Internet]. 2020 Dec. 9 [cited 2024 Jun. 10];56:e00222. Available from: https://www.journals.usp.br/bjps/article/view/181157